01:35:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cline Scientific är verksamma inom bioteknik. Bolaget är specialiserade inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.

Kalender

2023-02-24 Bokslutskommuniké 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-25 Kvartalsrapport 2020-Q2
2020-02-27 Ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-05-08 Ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-03 Ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-11 Kvartalsrapport 2017-Q2
2017-03-21 Ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 Kvartalsrapport 2016-Q1
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2022-04-12 08:30:00

Cline Scientific AB ("Cline" or "The Company") has now completed the first stage related to the ex-vivo testing of its cartilage repair product, StemCART, on human cartilage tissue. Cline has carried out 12 implantation experiments with patient specimens according to the plan and protocol. Initial results show encouraging performance.

The supporting matrix, which has been developed for use together with the cartilage cells, demonstrated the expected functionality in successfully fixing cells to the area of interest, which is one key aim of the ex-vivo testing.

The ex-vivo tests continue and will be expanded with tissue of different cartilage origin. The plan is to carry out 24 more experiments in several stages. Results from these will be communicated after the completion of each stage.

These proof of concept tests are an important step in validating the StemCART product concept and moving StemCART to the next development stage.

Next steps for StemCART
StemCART is a preclinical Advanced Therapy Medical Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. To achieve this, Cline will continue preparing for in-human clinical trials, including scaling up production into a GMP facility, developing QA/QC methods, and the necessary safety testing and documentation for a clinical trial application. Cline envisions out-licensing StemCART to a commercial partner following successful phase I trials.

About the ex-vivo testing
Beginning in January 2022, Cline has received cartilage tissue from patients undergoing orthopedic prosthetic surgery with the help of our clinical collaborators. The team then induces artificial cartilage damage to mimic joint injuries and then implants the cells and matrix together at the injury site of the tissue sample. The aim is to show that Cline's unique method successfully differentiates iPSCs into functional chondrocyte cells, that the matrix successfully supports the cells in place, and that healing of injured cartilage tissue is induced.

For more information, please contact:
Hanne Evenbratt, VP - Research & Development
Email: hanne.evenbratt@clinescientific.com
Phone: +46 704 88 79 23
Website: www.clinescientific.com